The Japanese Study Group of Insulin Therapy for Childhood and Adolescent Diabetes, Kyoto 604-0835, Japan.
Department of Pediatrics, Niigata City General Hospital, Niigata 950-1197, Japan.
Endocr J. 2023 Jul 28;70(7):677-685. doi: 10.1507/endocrj.EJ22-0379. Epub 2023 May 4.
Prevention of hypoglycemia is an important strategy for glycemic management in patients with type 1 diabetes mellitus (T1D). Hypoglycemia is difficult to recognize at night while sleeping, particularly when using multiple daily injection (MDI) insulin therapy rather than sensor-augmented insulin-pump therapy. Therefore, it is possible that patients with T1D are at higher risk of nocturnal hypoglycemia when insulin is administered using an MDI regimen. We investigated nocturnal hypoglycemia in 50 pediatric patients with T1D on MDI insulin therapy using data from an intermittently scanned continuous glucose monitoring (isCGM) system. Hypoglycemia was observed on 446 of the 1,270 nights studied. Most of the hypoglycemic episodes were severe (blood glucose <54 mg/dL). On nights when hypoglycemia occurred, the blood glucose concentrations measured using finger-stick blood glucose monitoring (FSGM) before sleep and the next morning were lower than nights when hypoglycemia did not occur. However, few values were below the normal blood glucose range, suggesting that FSGM alone may be insufficient to detect nocturnal hypoglycemia. Approximately 7% of time was spent below the normal glucose range during the 10 hours from 21:00 to 7:00 the next morning. This result suggests that the patients on MDI insulin therapy could end up spending more time in hypoglycemia than is recommended by the American Diabetes Association (time below range <4.0% of time per day). Monitoring glucose levels overnight using an isCGM sensor may improve glycemic management via automatic detection of blood glucose peaks and troughs.
预防低血糖是 1 型糖尿病(T1D)患者血糖管理的重要策略。夜间睡眠时低血糖难以察觉,尤其是使用多次每日注射(MDI)胰岛素治疗而非传感器增强型胰岛素泵治疗时。因此,使用 MDI 方案给药时,T1D 患者夜间发生低血糖的风险可能更高。我们使用间歇性扫描连续血糖监测(isCGM)系统的数据,调查了 50 名接受 MDI 胰岛素治疗的儿科 T1D 患者的夜间低血糖情况。在研究的 1270 个夜晚中,有 446 个夜晚出现了低血糖。大多数低血糖发作都很严重(血糖<54mg/dL)。发生低血糖的夜晚,睡前和次日清晨手指血糖监测(FSGM)测量的血糖浓度低于未发生低血糖的夜晚。然而,很少有数值低于正常血糖范围,这表明单独使用 FSGM 可能不足以检测夜间低血糖。在晚上 9 点到次日早上 7 点的 10 小时内,约有 7%的时间血糖低于正常范围。这一结果表明,接受 MDI 胰岛素治疗的患者可能会花费更多时间处于低血糖状态,而这超出了美国糖尿病协会的建议(每天低于范围的时间<4.0%)。使用 isCGM 传感器整夜监测血糖水平,可能通过自动检测血糖峰值和低谷来改善血糖管理。